top of page

LET SCIENCE DO THE TALKING

 

We are a clinical stage drug discovery and development biotech that uses a target-centric approach and classical medicinal chemistry to create new medicines

Metastatic melanoma cells

Photo by National Cancer Institute

 
CURADEV IN THE NEWS

Memorial Sloan Kettering Cancer Center and Curadev are expanding their collaboration through the MSK Therapeutics Accelerator program to expand the Phase 1 clinical trial currently underway at MSK with CRD3874-SI, Curadev’s first-in-class allosteric STING agonist, to several types of cancers

Mountains

ABOUT
US

Curadev is a clinical stage biotech company, dedicated to discovering and developing novel small molecule therapeutics for the treatment of intractable diseases. Utilizing a target-centric approach, innovative screening schemes and traditional wet-lab chemistry and pharmacology, Curadev has built an impressive portfolio of discovery research programs, resulting in patent-protected drug candidates that modulate next-generation drug targets.

About us
bottom of page